INFANRIX HEXA

Χώρα: Ινδονησία

Γλώσσα: Ινδονησιακά

Πηγή: Badan Pengawas Obat dan Makanan RI - Indonesian Food and Drug Supervisory Agency

Κατεβάστε Αρχείο Π.Χ.Π. (SPC)
01-01-2018

Δραστική ουσία:

DIPHTERIA TOXOID PROTEIN; FHA; FILAMENTOUS HEMAGGLUTININ; HAEMOPHILUS INFLUENZAE TYPE B POLYSACCHARIDE; HEPATITIS B SURFACE ANTIGEN (HBS AG); INACTIVATED POLIO VIRUS TYPE 1; INACTIVATED POLIO VIRUS TYPE 2; INACTIVATED POLIO VIRUS TYPE 3; PERTACTIN; PERTUSSISTOXOID MED ALUMINIUMHYDROXID; TETANUS TOXOID

Διαθέσιμο από:

SMITH KLINE BEECHAM PHARMACEUTICAL IND. - Indonesia

INN (Διεθνής Όνομα):

DIPHTERIA TOXOID PROTEIN; FHA; FILAMENTOUS HEMAGGLUTININ; HAEMOPHILUS INFLUENZAE TYPE B POLYSACCHARIDE; HEPATITIS B SURFACE ANTIGEN (HBS AG); INACTIVATED POLIO VIRUS TYPE 1; INACTIVATED POLIO VIRUS TYPE 2; INACTIVATED POLIO VIRUS TYPE 3; PERTACTIN; PERTUSSISTOXOID MED ALUMINIUMHYDROXID; TETANUS TOXOID

Φαρμακοτεχνική μορφή:

CAIRAN INJEKSI

Μονάδες σε πακέτο:

DUS, 1 PRE-FILLED SYRINGE @ 0,5 ML + 1 VIAL @ 0,5 ML

Κατασκευάζεται από:

GLAXO SMITHKLINE BIOLOGICALS-Belgium

Ημερομηνία της άδειας:

2018-01-23

Αρχείο Π.Χ.Π.

                                _Page 1 of 10_
INFANRIX HEXA
™
COMBINED DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS, HEPATITIS B, ENHANCED
INACTIVATED POLIO
VACCINE AND _HAEMOPHILUS INFLUENZAE_ TYPE B VACCINE
QUALITATIVE AND QUANTITATIVE COMPOSITION
After reconstitution, 1 dose (0.5 mL) contains:
Diphtheria toxoid
1
not less than 30 International Units (IU)
Tetanus toxoid
1
not less than 40 International Units (IU)
_Bordetella pertussis_ antigens
Pertussis toxoid
1
25 micrograms
Filamentous Haemagglutinin
1
25 micrograms
Pertactin
1
8 micrograms
Hepatitis B surface antigen
2,3
10 micrograms
Poliovirus (inactivated)
type 1 (Mahoney strain)
4
40 D-antigen unit
type 2 (MEF-1 strain)
4
8 D-antigen unit
type 3 (Saukett strain)
4
32 D-antigen unit
_Haemophilus influenzae_ type b polysaccharide
10 micrograms
(polyribosylribitol phosphate)
3
conjugated to tetanus toxoid as carrier protein
20 - 40 micrograms
1
adsorbed on aluminium hydroxide, hydrated (Al(OH)
3
)
0.5 milligrams Al
3+
2
produced in yeast cells (_Saccharomyces cerevisiae_) by recombinant
DNA technology
3
adsorbed on aluminium phosphate (AlPO
4
)
0.32 milligrams Al
3+
4
propagated in VERO cells
The DTPa-HBV-IPV component is presented as a turbid white suspension.
Upon storage, a white
deposit and clear supernatant can be observed.
The Hib component is presented as a white powder.
For excipients, see _List of Excipients_.
PHARMACEUTICAL FORM
Powder and suspension for suspension for injection.
CLINICAL PARTICULARS
INDICATIONS
_INFANRIX HEXA_
_™_
is indicated for primary and booster vaccination of infants against
diphtheria,
tetanus, pertussis, hepatitis B, poliomyelitis and _Haemophilus
influenzae_ type b.
DOSAGE AND ADMINISTRATION
POSOLOGY
The primary vaccination schedule consists of two or three doses (of
0.5 mL) which should be
administered according to official recommendations (see
_Pharmacodynamic Effects_ for schedules
evaluated in clinical trials). _ INFANRIX HEXA_
_™_
can be considered for the booster if the antigen
composition is in accordance with the official recommendations.
PRI
                                
                                Διαβάστε το πλήρες έγγραφο
                                
                            

Αναζήτηση ειδοποιήσεων που σχετίζονται με αυτό το προϊόν

Προβολή ιστορικού εγγράφων